Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer.
More papers using
United States. In Oncol Lett, 31 Dec 2015
Furthermore, in the presence of maximum cytostatic drug concentrations, the drug-resistant phenotypes isolated from the parental drug-sensitive cell lines representing luminal A, HER-2-enriched and triple negative breast cancer exhibited an 11.5, 5.0 and 6.2 fold increase in cell growth, and a 5.6, 5.4 and 4.4 fold increase in the number of AI colonies, respectively, compared with the drug-sensitive controls.
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
In PLoS ONE, 2009
... Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, Ventana Medical Systems). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
In Breast Cancer Research : BCR, 2008
... (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and HER2 (A085 antibody, Dako). A case of primary small cell carcinoma of the breast
In Pathology Research International, 2006
... antibodies were used: estrogen receptor (Novocastra, clone 6F11, 1 : 100), progesterone receptor (Novocastra, clone 16, 1 : 100), c-erbB-2 oncoprotein (Dako, HER-2), mammoglobin (Dako, clone ... The annexins
In Breast Cancer Research : BCR, 2003
... HER2/neu immunohistochemistryDako, polyclonal ... Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis
In Pathology Research International, 2002
... hours in a humidity chamber using the following dilutions: p53 (clone DO-7, titer 1 : 50, Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, ...